Mesoblast Limited ADR (MESO)
NASDAQ: MESOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
MESO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.81B
- Forward P/E
- 30.64
- EPS (TTM)
- -$0.44
- Dividend yield
- None
- 52-week range
- 13.05 – 21.50
- Day range
- 13.71 – 14.10
- Volume / Avg
- 240.62K / 236.60K
- Beta
- —
- Shares outstanding
- 129.85M
52-week range
MESO stock today
On Oct 7, MESO ended the session at $13.94, adding $0.33 (2.42%), versus the S&P 500's 0.22% decline. At this level, MESO sits near the bottom of its 52-week range of $13.05 to $21.50: 35.2% below the high, set on Jan 9, 2026 and 6.8% above the low. MESO is down 22.7% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 22.9%.
Mesoblast has posted a net loss over the last twelve months (EPS of -$0.44), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Mesoblast
Company profileMesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
- Headquarters
- Melbourne, VIC
- Employees
- 108
- IPO year
- 2015
- Website
- mesoblast.com
Analyst forecast
ForecastConsensus (3 analysts)
buy
Avg. price target
$37.00+165.42%
- Strong buy 2
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Mesoblast peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NVAXNovavax Inc. | 11.22 | -0.88% | $1.85B | vs MESO |
| VIRVir Biotechnology Inc. | 11.52 | -0.69% | $1.95B | vs MESO |
| VCELVericel Corporation | 40.74 | +1.72% | $2.09B | vs MESO |
| ALVOAlvotech | 5.85 | -4.72% | $2.09B | vs MESO |
| IMCRImmunocore Holdings plc ADR | 29.41 | -0.47% | $1.51B | vs MESO |
| BCRXBioCryst Pharmaceuticals Inc. | 8.40 | +5.66% | $2.15B | vs MESO |
| MAZEMaze Therapeutics Inc. | 26.25 | -0.68% | $1.46B | vs MESO |
| TSHATaysha Gene Therapies Inc. | 4.43 | +0.91% | $1.44B | vs MESO |
Indexes, lists and sector
Mesoblast stock FAQ
What is Mesoblast's stock price today?
MESO last traded at $13.94 as of Oct 7, 4:00 PM EDT, up 2.42% on the day. Prices are delayed at least 15 minutes.
Does Mesoblast pay a dividend?
No. Mesoblast does not currently pay a regular cash dividend.
Who is Mesoblast's CEO?
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) is the chief executive officer of Mesoblast Limited ADR, which has about 108 employees.
Has MESO ever split its stock?
Yes. The most recent MESO stock split was a 1-for-2 split on Jan 10, 2024.
What is the MESO 52-week high?
The 52-week high for MESO is $21.50 and the 52-week low is $13.05. The stock is currently 35.2% below its high.